A groundbreaking new study in ‘Nature,’ from a Novo Nordisk-funded research lab, boasts a drug that works better on mice than existing GLP-1s. A new paper released in Nature this week discusses a new therapy for obesity that researchers say leads to more weight loss in mice than existing GLP-1 weight-loss medications, such as Ozempic, Wegovy, and Zepbound, alone.